Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BEAT

BioTelemetry (BEAT) Stock Price, News & Analysis

BioTelemetry logo

About BioTelemetry Stock (NASDAQ:BEAT)

Advanced Chart

Key Stats

Today's Range
$2.10
$2.30
50-Day Range
$71.46
$72.27
52-Week Range
$1.45
$3.48
Volume
118,715 shs
Average Volume
104,431 shs
Market Capitalization
$43.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Buy

Company Overview

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

BioTelemetry Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

BEAT MarketRank™: 

BioTelemetry scored higher than 38% of companies evaluated by MarketBeat, and ranked 688th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioTelemetry has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BioTelemetry has received no research coverage in the past 90 days.

  • Read more about BioTelemetry's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioTelemetry is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioTelemetry is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioTelemetry has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.59% of the float of BioTelemetry has been sold short.
  • Short Interest Ratio / Days to Cover

    BioTelemetry has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioTelemetry has recently increased by 24.10%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    BioTelemetry does not currently pay a dividend.

  • Dividend Growth

    BioTelemetry does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.59% of the float of BioTelemetry has been sold short.
  • Short Interest Ratio / Days to Cover

    BioTelemetry has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioTelemetry has recently increased by 24.10%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, BioTelemetry insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      20.85% of the stock of BioTelemetry is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 7.77% of the stock of BioTelemetry is held by institutions.

    • Read more about BioTelemetry's insider trading history.
    Receive BEAT Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for BioTelemetry and its competitors with MarketBeat's FREE daily newsletter.

    BEAT Stock News Headlines

    HeartBeam Reports First Quarter 2025 Results
    Memorial Day Sale! 82% Off Disruptors and Dominators!
    Nvidia's robot breakthrough, unveiled by CEO Jensen Huang at CES, could spark a $24T revolution. He said the "ChatGPT moment" for robotics is near. I believe the lives of 65M Americans could be impacted – this year. And one $7 stock could be the biggest winner.
    See More Headlines

    BEAT Stock Analysis - Frequently Asked Questions

    BioTelemetry, Inc. (NASDAQ:BEAT) announced its quarterly earnings results on Tuesday, May, 13th. The medical research company reported ($0.18) earnings per share for the quarter.
    Read the conference call transcript
    .

    BioTelemetry (BEAT) raised $16 million in an initial public offering on Thursday, November 11th 2021. The company issued 2,750,000 shares at $5.50-$6.50 per share.

    Based on aggregate information from My MarketBeat watchlists, some other companies that BioTelemetry investors own include NVIDIA (NVDA), Meta Platforms (META), Bristol-Myers Squibb (BMY), Intel (INTC), Micron Technology (MU), PayPal (PYPL) and AbbVie (ABBV).

    Company Calendar

    Last Earnings
    5/13/2025
    Today
    5/24/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Surgical & medical instruments
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:BEAT
    Fax
    N/A
    Employees
    1,700
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $8.00
    High Stock Price Target
    $8.00
    Low Stock Price Target
    $8.00
    Potential Upside/Downside
    +385.4%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-14,640,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $0.61 per share
    Price / Book
    2.70

    Miscellaneous

    Free Float
    21,105,000
    Market Cap
    $43.95 million
    Optionable
    Not Optionable
    Beta
    -0.71
    The Best High-Yield Dividend Stocks for 2025 Cover

    Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

    Get This Free Report

    This page (NASDAQ:BEAT) was last updated on 5/24/2025 by MarketBeat.com Staff
    From Our Partners